Leucine is a better priming agent than arginine for insulin secretion in gliclazide treated NIDDM

Leucine is a better priming agent than arginine for insulin secretion in gliclazide treated NIDDM

Detalhes bibliográficos
Principais autores:	Matthews, DR, Boland, O
Formato:	Journal article
Publicado em:	1997

Registros relacionados

The stimulation of insulin secretion in non-insulin-dependent diabetic patients by amino acids and gliclazide in the basal and hyperglycemic state.
por: Matthews, DR, et al.
Publicado em: (1997)

Pathogenesis of NIDDM--a disease of deficient insulin secretion.
por: Turner, R, et al.
Publicado em: (1988)

The physiological action of gliclazide: beta-cell function and insulin resistance.
por: Matthews, DR, et al.
Publicado em: (1991)

Insulin use in NIDDM. Rationale based on pathophysiology of disease.
por: Turner, R, et al.
Publicado em: (1990)

Lipotoxic Nephropathy Is More Severe in Male than Female Rats N with Non-Insulin Diabetes Mellitus (NIDDM)
por: Jesus H. Dominguez, et al.
Publicado em: (2001-01-01)

CIGMA as a tool in the study of NIDDM.
por: Turner, R, et al.
Publicado em: (1988)

Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
por: Rachman, J, et al.
Publicado em: (1997)

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM
por: Rachman, J, et al.
Publicado em: (1996)

Specific insulin and proinsulin in normal glucose tolerant first-degree relatives of NIDDM patients
por: R. Coifman, et al.
Publicado em: (1999-01-01)

Segregation analysis of NIDDM in Caucasian families.
por: Cook, J, et al.
Publicado em: (1994)

Reduced sampling protocols in estimation of insulin sensitivity and glucose effectiveness using the minimal - model in NIDDM
por: Ismail, I.S., et al.
Publicado em: (1993)

Chewing the fat for better insulin secretion
por: Sofianos Andrikopoulos
Publicado em: (2016-01-01)

Fabrication and Characterization of Gliclazide Nanocrystals
por: Nagaraju Ravouru, et al.
Publicado em: (2018-08-01)

Insulin Secretion in Response to L-Arginine under Decreasing Tetrahydrobiopterin Content
por: Ishii Masakazu, et al.
Publicado em: (2008-02-01)

RESTING THE BETA-CELLS WITH INSULIN IN NIDDM DOES NOT IMPROVE BETA-CELL FUNCTION NOR PROINSULIN PROCESSING
por: Rachman, J, et al.
Publicado em: (1995)

No glycemic benefit from guar administration in NIDDM.
por: Holman, R, et al.
Publicado em: (1987)

Attenuation of lipid peroxidation and atherogenic factors in diabetic patients treated with gliclazide and metformin
por: Sujan Banik, et al.
Publicado em: (2018-01-01)

The primordial metabolism: an ancestral interconnection between leucine, arginine, and lysine biosynthesis
por: Paffetti Donatella, et al.
Publicado em: (2007-08-01)

Greater in vivo than in vitro pulsatility of insulin secretion with synchronized insulin and somatostatin secretory pulses.
por: Matthews, DR, et al.
Publicado em: (1987)

Pengaruh captopril terhadap albumminuria pada penderita non insulin dependent diabetes mellitus (NIDDM) dengan albuminura
por: , WIDIANA, I Gde Raka, et al.
Publicado em: (1993)

Pengaruh captopril terhadap albumminuria pada penderita non insulin dependent diabetes mellitus (NIDDM) dengan albuminura
por: , WIDIANA, I Gde Raka, et al.
Publicado em: (1993)

Chromosome 4q locus associated with insulin resistance in Pima Indians. Studies in three European NIDDM populations.
por: Humphreys, P, et al.
Publicado em: (1994)

Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
por: Rachman, J, et al.
Publicado em: (1998)

A new Herbal preparation with hypoglycemic effect used in treatment of Non Insulin Dependent Diabetes Mellitus [NIDDM]
por: Omar Ahmed Abass
Publicado em: (2012-06-01)

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.
por: Belcher, G, et al.
Publicado em: (2005)

Fabrication and Characterization of Gliclazide Loaded Microcapsules
por: Muhammad Asad, et al.
Publicado em: (2014-12-01)

Methodology of Gliclazide Detection in Biological Samples
por: Serhii I. Merzlikin, et al.

Cocrystallization of gliclazide with improved physicochemical properties
por: Shivarani Eesam, et al.
Publicado em: (2021-06-01)

Thyroid dysfunction and its relation with diabetes mellitus (NIDDM)
por: H.R.Bazrafshan (M.D), et al.
Publicado em: (2000-03-01)

Effect of antiretroviral drugs on the pharmacodynamics of gliclazide with respect to glucose&ndash;insulin homeostasis in animal models
por: S&nbsp;K Mastan, et al.
Publicado em: (2009-12-01)

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
por: Rachman, J, et al.
Publicado em: (1996)

Risk factors predicting progression of diabetic retinopathy over six years in 1579 NIDDM patients
por: Stratton, I, et al.
Publicado em: (1996)

IT IS BETTER TO PREVENT DISEASE THAN TREAT IT
por: N. V. Dolgushina
Publicado em: (2015-12-01)

IT IS BETTER TO PREVENT DISEASE THAN TREAT IT
por: N. V. Dolgushina
Publicado em: (2015-12-01)

IT IS BETTER TO PREVENT DISEASE THAN TREAT IT
por: N. V. Dolgushina
Publicado em: (2015-12-01)

Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension
por: Sunitha Sampathi, et al.
Publicado em: (2022-09-01)

Insulin secretion--the ups and downs.
por: Matthews, DR
Publicado em: (1987)

Treatment of NIDDM - Progressive requirement for polypharmacy to attain glycaemic goals
por: Cull, C, et al.
Publicado em: (1997)

Competitive Repression of the artPIQM Operon for Arginine and Ornithine Transport by Arginine Repressor and Leucine-Responsive Regulatory Protein in Escherichia coli
por: Oscar E. Torres Montaguth, et al.
Publicado em: (2019-07-01)

Hyperinsulinemia and insulin resistance are associated with multiple abnormalities of lipoprotein subclasses in glucose-tolerant relatives of NIDDM patients. Botnia Study Group.
por: M Tilly-Kiesi, et al.
Publicado em: (1996-01-01)